The moves are part of an effort to consolidate and reduce costs related to administrative, finance, and operational support functions.
CGI will provide target identification and biomarker discovery services for three cancer drugs that BeiGene is currently developing.
The firm saw a 204 percent increase in clinical services test volume year over year driven by increased offerings in several testing services.
The companies will work together to advance the use of ApoCell's rare cell isolation platform for cancer molecular profiling and monitoring in clinical trials.
The partners said they will also combine their respective expertise to offer pharmaceutical companies help in developing companion diagnostics for oncology.
The recent failure of Bristol-Myers Squibb's lung cancer immunotherapy to meet its primary endpoint demonstrates the challenge of working with imperfect biomarkers.
The company said it plans to use the proceeds of the offering for general corporate purposes.
The firm said its Focus::Myeloid NGS-based panel for myeloid malignancies provides information for diagnosis, prognosis, treatment, and risk stratification of patients.
The company's revenues saw strong growth on gains in its biopharma services and clinical services operations.
Cancer Genetics will provide the services to support H3's development of H3B-8800, a Phase I small molecule-based blood cancer drug candidate.
A man has confessed to the rape and murder of developmental biologist Suzanne Eaton, according to the New York Times.
The Irish Times reports that US lawmakers and law enforcement agencies are concerned about ties between the US and Chinese genomics firms.
Parents of children with spinal muscular atrophy tell the Washington Post they are pushing to get insurance coverage of Novartis's Zolgensma.
In PNAS this week: gene mutations in individuals with syndromic craniosynostosis, putative colorectal cancer drivers, and more.